Streetbeat News

Earnings

ETON

Eton Pharmaceuticals (NASDAQ:ETON) reported Q4 earnings with an EPS of $-0.09, missing estimates by -125.0% and a revenue decrease of $1.19 million from the previous year. This follows a pattern of past earnings where a beat or miss on EPS estimates led to significant share price movements.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 8:20 pm

ALLO

Allogene Therapeutics (NASDAQ:ALLO) reported Q4 earnings with an EPS of $-0.51, missing estimates by -13.0% against an expected $-0.45. Revenue decreased by $26 thousand from the previous year. Despite beating EPS estimates in Q3 2023, which led to an 18.0% share price increase, this quarter's performance fell short.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 8:20 pm

GETY

Getty Images Holdings reported better-than-expected Q4 revenue results and issued positive FY24 revenue guidance, causing its shares to trade higher.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 8:20 pm

ADBE

Adobe Inc (NASDAQ:ADBE) reported Q1 financial results with an 11% year-over-year revenue increase to $5.18 billion, surpassing estimates. Earnings per share were $4.48, beating the $4.38 estimate. Adobe has exceeded analyst expectations for five consecutive quarters. The company announced a new $25 billion stock repurchase program and provided a slightly softer Q2 revenue outlook than expected, forecasting $5.25 billion to $5.30 billion against a $5.31 billion estimate.

Portfolio Pulse from Adam Eckert

March 14, 2024 | 8:19 pm

ULTA

Ulta Beauty's shares dropped following its Q4 financial results announcement and FY24 revenue guidance, which fell below expectations. However, the company's board approved a new $2.0 billion share repurchase program.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 8:18 pm

ZUMZ

Zumiez reported its Q4 earnings with an EPS of $(1.73), surpassing the estimated EPS. The company's sales reached $281.82M, also beating the expected $275.87M.

Portfolio Pulse from Happy Mohamed

March 14, 2024 | 8:17 pm

ALLO

Allogene Therapeutics reported Q4 2023 earnings with a GAAP EPS of $(0.51), missing the $(0.46) estimate, and sales of $21,000, missing the $23,571 estimate. This represents a 23.88% increase in EPS losses and a 19.23% decrease in sales from the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 8:17 pm

VSTM

Verastem (NASDAQ:VSTM) reported a Q4 2023 adjusted EPS loss of $(1.10), missing the consensus estimate of $(0.62) by 77.42%.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 8:17 pm

ETON

Eton Pharmaceuticals (NASDAQ:ETON) reported Q4 2023 earnings with a GAAP EPS of $(0.09), missing the $(0.04) estimate, and sales of $7.313M, missing the $7.700M estimate. This represents a 13.94% decrease in sales compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 8:17 pm

EVCM

EverCommerce forecasts Q1 revenue of $160.5M-$163.5M, below the estimated $173.048M, and full-year 2024 revenue of $676M-$696M, under the $731.945M estimate. Adjusted EBITDA is expected to be $36M-$38M for Q1 and $167M-$176M for 2024.

Portfolio Pulse from Benzinga Newsdesk

March 14, 2024 | 8:16 pm